Search Protocols under revision. Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupSarcomasSarcomas (ped.)DiseaseEwing SarcomaSubgroupICD10C40.-C41.-MeSHSarcoma, EwingSequenceAntineoplastic therapySubstanceCyclophosphamideTopotecanSubstanceCyclophosphamideTopotecanSubstanceCyclophosphamideTopotecanSubstanceCyclophosphamideTopotecanNo. Substances2 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSubstanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSubstanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimSubstanceBalanced Crystalloid SolutionDexamethasoneGranisetronPegfilgrastimNo. Substances4Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationRelapse therapyTherapy phaseTherapy intentionpalliativeRisksEmetogenicity (MASCC/ESMO)Febrile NeutropeniaInfectionsNeutropenia only studiesPublicationAuthorHunold ADiseaserezidivierendes oder refraktäres Ewing Sarkom, ZweitlinieOriginDepartment of Pediatric Hematology and Oncology, University Children's Hospital, Muenster, GermanyProtocols in Revision 1 protocol foundTopotecan 0.75 / Cyclophosphamide 250, Ewing Sarcoma (PID1180 V1.0)
